Forte's Value Destruction Analysis

Why We're Here Today We believe Forte is in need of stockholder-designated directors following years of poor performance and worst-in- class governance under Chairman and CEO Dr. Paul Wagner and the current Board: × Extremely Dilutive Capital Raises × Appointment of Director with 20-Year Relationship to Dr. Wagner × X Blatant Disregard for Stockholder Wishes Delay of Stockholder Meeting × Adopting "Poison Pill" with Low 10% Trigger × Failure to Comply with SEC Rule 14a-13(a)(3) Concerned Stockholders of Forte Biosciences | 5

View entire presentation